GEN Exclusives

More »

GEN News Highlights

More »
Jan 2, 2008

Sepracor In-Licenses Phase III Epilepsy Drug from Bial for $75M Upfront

  • Sepracor exclusively licensed Bial's antiepileptic compound for development and commercialization in the U.S. and Canada. Bial could make over $175 million through this deal.

    Bial will receive $75 million upfront. The company may also earn milestone-based payments totaling $100 million. Sepracor will be responsible for filing the NDA, seeking marketing approval from the FDA, and commercialization. Sepracor anticipates that the NDA will be submitted in late 2008 or early 2009.

    Bial will also earn compensation for providing finished product to Sepracor. The firm may also receive milestone fees upon FDA approval of the compound in additional indications.

    BIA 2-093 has reportedly been designed to offer patients suffering with partial epilepsy additional control of their seizures and improved quality of life.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »